Sinotherapeutics (SH:688247) Zheng Quan Ri Bao·2026-02-11 11:41Core Viewpoint - The company is focusing on high-end generic drugs while accelerating the development of improved new drugs, with a specific emphasis on the antifungal field through its self-developed project XT-0043, which has shown excellent safety and efficacy in Phase II clinical trials and is moving towards Phase III trials [2] Group 1 - The company is deeply engaged in the high-end generic drug market [2] - The first self-developed improved new drug project, XT-0043, is aimed at the antifungal area [2] - XT-0043 has demonstrated outstanding safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [2] Group 2 - The company is currently focusing on advancing the Phase III clinical trial based on the data obtained from Phase II [2]